Similar articles for PMID: 21422125

Year	Number of Results
2001	1
2002	2
2003	2
2004	1
2005	2
2006	1
2007	4
2008	5
2009	1
2010	2
2011	6
2012	4
2013	10
2014	4
2015	6
2016	11
2017	11
2018	10
2019	10
2020	7
2021	9
2022	5
2024	0

1

The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.

McAlister FA, Zhang J, Tonelli M, Klarenbach S, Manns BJ, Hemmelgarn BR; Alberta Kidney Disease Network. McAlister FA, et al. CMAJ. 2011 Apr 5;183(6):655-62. doi: 10.1503/cmaj.101333. Epub 2011 Mar 21. CMAJ. 2011. PMID: 21422125 Free PMC article.

2

Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.

Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R. Kurnik D, et al. Clin Ther. 2011 Apr;33(4):456-64. doi: 10.1016/j.clinthera.2011.04.011. Clin Ther. 2011. PMID: 21635991

3

Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.

Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Stürmer T, Robinson JG. Fang G, et al. Pharmacotherapy. 2018 Jan;38(1):29-41. doi: 10.1002/phar.2051. Epub 2017 Dec 11. Pharmacotherapy. 2018. PMID: 29059475 Free PMC article.

4

Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.

Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K; Hypertension Outcome, Surveillance Team. Butt DA, et al. J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271. J Bone Miner Res. 2014. PMID: 24806397 Free article.

5

Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.

Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, Khoshniat-Rad F, Sood MM, Zheng S, Pravoverov L, Nesrallah GE, Garg AX, Go AS. Parikh RV, et al. Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006415. doi: 10.1161/CIRCOUTCOMES.119.006415. Epub 2020 Sep 2. Circ Cardiovasc Qual Outcomes. 2020. PMID: 32873054 Free PMC article.

6

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. Heerspink HJ, et al. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4. Eur J Prev Cardiol. 2014. PMID: 24191305 Clinical Trial.

7

Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.

[No authors listed] [No authors listed] Prescrire Int. 2005 Oct;14(79):180-6. Prescrire Int. 2005. PMID: 16285075

8

Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?

Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L. Silvariño R, et al. Nephron. 2019;143(2):100-107. doi: 10.1159/000500925. Epub 2019 Jun 14. Nephron. 2019. PMID: 31203280

9

The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial.

Saglimbene V, Palmer SC, Ruospo M, Natale P, Maione A, Nicolucci A, Vecchio M, Tognoni G, Craig JC, Pellegrini F, Lucisano G, Hegbrant J, Ariano R, Lamacchia O, Sasso A, Morano S, Filardi T, De Cosmo S, Pugliese G, Procaccini DA, Gesualdo L, Palasciano G, Johnson DW, Tonelli M, Strippoli GFM; Long-Term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) Investigators. Saglimbene V, et al. J Am Soc Nephrol. 2018 Dec;29(12):2890-2899. doi: 10.1681/ASN.2018040443. Epub 2018 Nov 12. J Am Soc Nephrol. 2018. PMID: 30420421 Free PMC article. Clinical Trial.

10

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Phillips CO, et al. Arch Intern Med. 2007 Oct 8;167(18):1930-6. doi: 10.1001/archinte.167.18.1930. Arch Intern Med. 2007. PMID: 17923591 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year